It looks like a straight-up swap between Boston venture capital firm Third Rock Ventures and Cambridge start-up Constellation Pharmaceuticals Inc. --- Keith E. Dionne is leaving Third Rock to replace Constellation chief executive Mark A. Goldsmith, who is off to the West Coast to be a venture partner in Third Rock’s San Francisco office.
Constellation looks to develop disease treatments from epigenetics, the study of molecular changes in cells that can activate or deactivate genes without affecting the underlying DNA code. To date, the company has raised more than $70 million from investors including Third Rock.
Goldsmith will continue his involvement with Constellation as executive chairman of its board of directors, the company said in a press release.
Dionne joins Constellation from Third Rock, where he served as an entrepreneur-in-residence. Previously, he was chief executive at Surface Logix Inc.
Before entering the private sector, Goldsmith, an M.D., practiced medicine on the faculty of the University of California-San Francisco School of Medicine, Third Rock noted in a press release of its own.